Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support cancer research at Fred Hutch.

NOTE: Last year’s event sold out in advance, and space is limited. Buy your tickets early to save your seat.

PROGRAM

1 p.m. | Registration

1:30 p.m. | Welcome Remarks 

• Kelly O’Brien, vice president of philanthropy, Fred Hutch*
• Luke Timmerman

1:40 p.m. | Why I’m Doing the Kilimanjaro Climb to Fight Cancer (60 seconds each)

• Kristin Anderson, postdoctoral fellow, Fred Hutch Phil Greenberg Lab, Society for Immunotherapy of Cancer Presidential Award-winning young investigator*
• Kelly O’Brien, vice president of philanthropy, Fred Hutch*
• Bob More, partner, Alta Partners*

1:45 p.m. | New Ideas for Cancer (10 minutes each)

• Clayton Knox, chief operating officer, Mavupharma
• Stanford Peng, EVP of R&D and Chief Medical Officer, Alpine Immune Sciences
• Carla Grandori, CEO, SEngine Precision Medicine
• Sam Blackman, founder and chief medical officer, Day One Therapeutics
• Heidi Hagen, co-founder and chief strategy officer, Vineti*

2:40 p.m. | Cancer Investment Landscape. Separating the Hype from the Reality.

• Steve Harr, co-founder and CEO, Sana Biotechnology (moderator)
• Peter Thompson, private equity partner, OrbiMed; co-founder, Silverback Therapeutics
• Racquel Bracken, vice president, Venrock
• Tom Daniel, venture partner, ARCH Venture Partners
• Thong Le, CEO, Accelerator Life Science Partners

3:15 p.m. | BREAK

3:45 p.m. | New Information, New Insights for Cancer & Beyond

• Charlotte Hubbert, partner, Gates Foundation Venture Capital (moderator)
• Chad Robins, co-founder and CEO, Adaptive Biotechnologies
• Brad Gray, CEO, NanoString Technologies

4:20 p.m. | The Costs for Patients

• Veena Shankaran, co-director, Hutchinson Institute for Cancer Outcomes Research
• Robin Yabroff, strategic director, economic burden of cancer, American Cancer Society

5:00 p.m. | Closing Conversation. The Future of Data Science in Cancer

• Gary Gilliland, president and director, Fred Hutch
• Matt McIlwain, chairman of the board of trustees, Fred Hutch
• Luke Timmerman (moderator)

5:30 p.m. | A Word on the Kilimanjaro Climb to Fight Cancer

• Luke Timmerman

5:35 p.m. | NETWORKING

6:00 p.m. | END

Sponsors:

• Veracyte
• Nektar Therapeutics
• Alexandria Real Estate Equities 
• Takeda Pharmaceuticals
• Foundation Medicine
• Madryn Asset Management
• Servier
• Sofinnova
• ATUM Bio
• 5AM Ventures
• Mirati Therapeutics, Inc
• Pfizer
• Blueprint Medicines
• Zymeworks

*Denotes Kilimanjaro climber